Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 4/20 | 0.70 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.70 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.70 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.70 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.70 |
| ▸ | SERPINE1 | P05121 | 5/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TYR | P14679 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28022507 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15650775 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15650867 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29374035 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2764415 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15650486 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL1883477 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15650438 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15648827 | 1.00 | ESR1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL15650000 | 0.98 | SERPINE1 (0.70) | ESR1AKR1C4AKR1C3AKR1C2AKR1C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1282730-A | Compounds with particular structure and anticancer activity and its preparing process | YANG ZHENHUA (CN) | 2001-02-07 | — | — | CN | claimed |
| US-20250275997-A1 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester | BONAFIDE HEALTH, LLC | 2025-09-04 | — | — | US | disclosed |
| US-12303524-B2 | Compositions comprising S-adenosylmethionine and a gallic acid ester | MSI-195 HOLDINGS, LLC (US) | 2025-05-20 | — | — | US | disclosed |
| US-20220193107-A1 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER | BONAFIDE HEALTH, LLC | 2022-06-23 | — | — | US | disclosed |
| US-20220031729-A1 | USE OF S-ADENOSYLMETHIONINE FOR PERSONALIZED TREATMENT OF DEPRESSION | Zentar LLC (US) | 2022-02-03 | — | — | US | disclosed |
| US-20200129537-A1 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER | MSI-195 HOLDINGS, LLC | 2020-04-30 | — | — | US | disclosed |
| US-20190022119-A1 | Compositions comprising S-Adenosylmethionine and a gallic acid ester | MSI-195 HOLDINGS, LLC | 2019-01-24 | — | — | US | disclosed |
| US-9925208-B2 | Compositions comprising S-adenosylmethionine and a gallic acid ester | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2018-03-27 | — | — | US | disclosed |
| US-9801896-B2 | Compositions comprising S-adenosylmethionine and a gallic acid ester | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2017-10-31 | — | — | US | disclosed |
| EP-3131557-A2 | NOVEL ADEMETIONINE FORMULATIONS | Methylation Sciences International SRL (BB) | 2017-02-22 | — | — | EP | disclosed |
| US-8975238-B2 | Compositions comprising S-adenosylmethionine and a gallic acid ester | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2015-03-10 | — | — | US | disclosed |
| US-20140220129-A1 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2014-08-07 | — | — | US | disclosed |
| WO-2014059522-A1 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER | METHYLATION SCIENCES INTERNATIONAL SRL (BB) | 2014-04-24 | — | — | WO | disclosed |
| US-7109364-B2 | Group of anti-cancer compounds with specific structure and their production method | YANG ZHENHUA | 2006-09-19 | — | — | US | disclosed |
| EP-1259470-A4 | A GROUP OF ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE AND THEIR PRODUCTION METHOD | YANG ZHENHUA (US) | 2005-06-15 | — | — | EP | disclosed |
| CN-1193002-C | Compounds with particular structure and anticancer activity and its preparing process | YANG ZHENHUA (CN) | 2005-03-16 | — | — | CN | disclosed |
| US-20040034242-A1 | Group of anti-cancer compounds with specific structure and their production method | YANG ZHENHUA (US) | 2004-02-19 | — | — | US | disclosed |
| EP-1259470-A2 | A GROUP OF ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE AND THEIR PRODUCTION METHOD | Yang, Zhenhua (US) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001059067-A2 | A GROUP OF ANTI-CANCER COMPOUNDS WITH SPECIFIC STRUCTURE AND THEIR PRODUCTION METHOD | YANG ZHENHUA (US) | 2001-08-16 | — | — | WO | disclosed |
| CN-1282730-A | Compounds with particular structure and anticancer activity and its preparing process | YANG ZHENHUA (CN) | 2001-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193107-A1 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
| US-20190022119-A1 | Compositions comprising S-Adenosylmethionine and a gallic acid ester | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
| US-20250275997-A1 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
| US-20200129537-A1 | COMPOSITIONS COMPRISING S-ADENOSYLMETHIONINE AND A GALLIC ACID ESTER | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
| US-20220031729-A1 | USE OF S-ADENOSYLMETHIONINE FOR PERSONALIZED TREATMENT OF DEPRESSION | BHMT2, BHMT, MAT2A | ESR1 1471/4885AKR1C4 2867/4885AKR1C3 2623/4885 |
| US-12303524-B2 | Compositions comprising S-adenosylmethionine and a gallic acid ester | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
| US-20140220129-A1 | Compositions Comprising S-Adenosylmethionine and a Gallic Acid Ester | BHMT2, BHMT, MAT1A | ESR1 598/4885AKR1C4 1989/4885AKR1C3 1733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.